Lansforsakringar Fondforvaltning Ab (Publ) Neurocrine Biosciences Inc Transaction History
Lansforsakringar Fondforvaltning Ab (Publ)
- $17 Billion
- Q2 2025
A detailed history of Lansforsakringar Fondforvaltning Ab (Publ) transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Lansforsakringar Fondforvaltning Ab (Publ) holds 31,491 shares of NBIX stock, worth $4.06 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
31,491
Previous 32,446
2.94%
Holding current value
$4.06 Million
Previous $3.59 Million
10.31%
% of portfolio
0.02%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding NBIX
# of Institutions
652Shares Held
100MCall Options Held
700KPut Options Held
237K-
Black Rock Inc. New York, NY14.2MShares$1.83 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.81MShares$1.26 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.57MShares$718 Million0.42% of portfolio
-
State Street Corp Boston, MA4.47MShares$576 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.09MShares$398 Million0.04% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12.3B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...